Global Regulatory Insights’ Post

In a recent ruling, the European Union Court has upheld a fine of €13.96 million (approximately Rs 125.62 crore) on Ipca Laboratories’ subsidiaries, Unichem and Niche Generics, related to a patent dispute settlement agreement with the Servier group. Key Details: - Entities Involved: Unichem Laboratories Ltd and Niche Generics Ltd, subsidiaries of Ipca Laboratories. - Dispute Background: The fine pertains to a settlement agreement over the Perindopril drug patent with Servier, a French pharmaceutical company. - Patent History: Perindopril, used for treating hypertension and heart failure, had its patent challenged by multiple companies, including Unichem and Niche. - Allegation: It was alleged that the settlement agreement breached EU competition law. Financial Impact: - Fine Amount: €13.96 million (approximately Rs 125.62 crore). - Provision Made: Ipca Labs and Unichem have already made provisions for the fine in their financial statements. - Company Statement: Ipca Laboratories has stated that there will be no material impact on the company’s operations due to this fine. Stay informed on significant legal and regulatory developments impacting the pharmaceutical industry with Global Regulatory Insights. #IpcaLabs #EUCourt #PatentDispute #Pharmaceuticals #CompetitionLaw #GRI

  • graphical user interface, text, application

To view or add a comment, sign in

Explore topics